Nationwide Validation Study of Diagnostic Algorithms for Inflammatory Bowel Disease in Korean National Health Insurance Service Database.

Nationwide Validation Study of Diagnostic Algorithms for Inflammatory Bowel Disease in Korean National Health Insurance Service Database. J Gastroenterol Hepatol. 2019 Sep 09;: Authors: Lee CK, Ha HJ, Oh SJ, Kim JW, Lee JK, Kim HS, Yoon SM, Kang SB, Kim ES, Kim TO, Na SY, Lee J, Kim SW, Koo HS, Park BK, Lee HH, Kim ES, Park JJ, Kwak MS, Cha JM, Ye BD, Choi CH, Kim HJ Abstract BACKGROUND/AIMS: We conducted a nationwide validation study of diagnostic algorithms to identify cases of inflammatory bowel disease (IBD) within…

Read More

Increased Risk of Idiopathic Pulmonary Fibrosis in Inflammatory Bowel Disease: A Nationwide Study.

Related Articles Increased Risk of Idiopathic Pulmonary Fibrosis in Inflammatory Bowel Disease: A Nationwide Study. J Gastroenterol Hepatol. 2019 Aug 16;: Authors: Kim J, Chun J, Lee C, Han K, Choi S, Lee J, Soh H, Choi K, Park S, Kang EA, Lee HJ, Im JP, Kim JS Abstract BACKGROUND AND AIM: The relationship between inflammatory bowel disease (IBD) and idiopathic pulmonary fibrosis (IPF) remains unclear. We evaluated the risk for developing IPF in patients with IBD using a nationwide, population-based study. METHODS: Using claims data from the National Health…

Read More

Infliximab for Very Early-Onset Inflammatory Bowel Disease: A Tertiary Center Experience in Japan.

Infliximab for Very Early-Onset Inflammatory Bowel Disease: A Tertiary Center Experience in Japan. J Gastroenterol Hepatol. 2019 Aug 19;: Authors: Takeuchi I, Kaburaki Y, Arai K, Shimizu H, Hirano Y, Nagata S, Shimizu T Abstract BACKGROUND AND AIM: Very early-onset inflammatory bowel disease (VEO-IBD), defined as IBD diagnosed before six years of age, tends to be refractory to conventional treatment for IBD. However, there have been a few reports about the usage of infliximab for VEO-IBD. This study aimed to evaluate the efficacy and safety of infliximab for VEO-IBD. METHODS:…

Read More

The Incidence and Risk Factors of Pneumocystis jirovecii Pneumonia in Korean Patients with Inflammatory Bowel Disease.

The Incidence and Risk Factors of Pneumocystis jirovecii Pneumonia in Korean Patients with Inflammatory Bowel Disease. J Gastroenterol Hepatol. 2019 Aug 14;: Authors: Nam K, Park SH, Lee J, Jo S, Kim SO, Noh S, Park JC, Kim JY, Kim J, Ham NS, Oh EH, Song EM, Hwang SW, Yang DH, Ye BD, Byeon JS, Myung SJ, Yang SK Abstract BACKGROUND AND AIM: Little is known whether routine prophylaxis against Pneumocystis jirovecii pneumonia (PJP) is needed in patients with inflammatory bowel disease (IBD) on immunosuppression, especially in Asian populations. We,…

Read More

Acceptability, Tolerability and Safety of Faecal Microbiota Transplantation in patients with active Ulcerative Colitis (AT&S Study).

Acceptability, Tolerability and Safety of Faecal Microbiota Transplantation in patients with active Ulcerative Colitis (AT&S Study). J Gastroenterol Hepatol. 2019 Aug 13;: Authors: Sood A, Singh A, Mahajan R, Midha V, Mehta V, Gupta YK, Narang V, Kaur K Abstract BACKGROUND: Faecal microbiota transplantation (FMT) targets gut microbiome dysbiosis and is an emerging therapy for ulcerative colitis (UC). Though initial results with FMT in patients with active UC are encouraging, data regarding its acceptability, tolerability and safety are scant. METHODS: A retrospective analysis of patients with active UC (Mayo clinic…

Read More

Impact of immunomodulator use on treatment persistence in patients with ulcerative colitis: a claims database analysis.

Related Articles Impact of immunomodulator use on treatment persistence in patients with ulcerative colitis: a claims database analysis. J Gastroenterol Hepatol. 2019 Aug 08;: Authors: Kobayashi T, Udagawa E, Uda A, Hibi T, Hisamatsu T Abstract BACKGROUND AND AIM: It is unclear how adding an anti-tumor necrosis factor-α (TNFα) agent to immunomodulator treatment, as a step-up strategy, affects long-term outcomes in ulcerative colitis. This retrospective study investigated persistence associated with biologic anti-TNFα agents combined with immunomodulators versus biologic monotherapy in patients with ulcerative colitis. METHODS: This was a longitudinal cohort…

Read More

Short- and long-term outcomes of Indigo naturalis treatment for inflammatory bowel disease.

Short- and long-term outcomes of Indigo naturalis treatment for inflammatory bowel disease. J Gastroenterol Hepatol. 2019 Aug 07;: Authors: Matsuno Y, Hirano A, Torisu T, Okamoto Y, Fuyuno Y, Fujioka S, Umeno J, Moriyama T, Nagai S, Hori Y, Fujiwara M, Kitazono T, Esaki M Abstract BACKGROUND AND AIM: Indigo naturalis (IN) is a traditional Chinese herbal medicine reported to be effective in inducing remission in ulcerative colitis (UC). We conducted a retrospective observational study to investigate the efficacy and safety of IN for induction and maintenance therapy in patients…

Read More

Association of FUT2 and ABO with Crohn’s disease in Koreans.

Association of FUT2 and ABO with Crohn’s disease in Koreans. J Gastroenterol Hepatol. 2019 Jul 01;: Authors: Ye BD, Kim BM, Jung S, Lee HS, Hong M, Kim K, Moon JW, Baek J, Oh EH, Hwang SW, Park SH, Yang SK, Song K Abstract BACKGROUND AND AIMS: Fucosyltransferase 2 (FUT2) at 19q13 is a well-established susceptibility locus for Crohn’s disease (CD) in Caucasians. FUT2 encodes α-1,2-fucosyltransferase that regulates the secretion of the ABO antigens in both gastrointestinal mucosa and secretory glands. Given that Crohn’s disease is thought to arise from…

Read More

Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission.

Related Articles Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission. J Gastroenterol Hepatol. 2019 Jun 06;: Authors: Wang Y, Wang J, Pekow J, Dalal S, Cohen RD, Ollech J, Israel A, Shogan BD, Micic D, Cannon L, Umanskiy K, Hurst R, Hyman N, Rubin DT, Sakuraba A Abstract BACKGROUND AND AIM: Vedolizumab (VDZ) has been used in inflammatory bowel disease (IBD) patients who failed anti-tumor necrosis factor (TNF) therapy. This study was to examine long-term outcome of IBD patients switching…

Read More
<< Go Back